Investigating how B-cells contribute to fighting triple negative breast cancer
The role of B-cells in the anti-tumor immune response in triple negative breast cancer
This study is looking at how certain immune cells called B-cells help fight triple negative breast cancer, with the hope of finding new ways to improve treatments for patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11075873 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of B-cells in the immune response against triple negative breast cancer (TNBC), a subtype known for its poor prognosis. By analyzing tumor-infiltrating B-cells, the study aims to uncover how these cells recognize tumor antigens and produce antibodies that may enhance the effectiveness of immunotherapy. The researchers will utilize advanced techniques like single-cell sequencing to identify specific B-cell receptors and their targets in TNBC. This approach could lead to new insights into how B-cells can be harnessed for better cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple negative breast cancer who are seeking innovative treatment options.
Not a fit: Patients with other types of breast cancer or those not diagnosed with cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for patients with triple negative breast cancer.
How similar studies have performed: While the role of T-cells in TNBC has been well-studied, the specific investigation of B-cells in this context is relatively novel and has not been extensively tested.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Downs-Canner, Stephanie M — Sloan-Kettering Inst Can Research
- Study coordinator: Downs-Canner, Stephanie M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.